BAILEY MORRIS: Open Payments
NPI 1699441980 · GULFPORT, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,167 in 173 payments from 41 companies in 2025. Trend: 2023 $2,066 · 2024 $2,971 · 2025 $3,167
Food & beverage: $3,098Education: $68
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 25 | $344 |
| Janssen Biotech, Inc. | 18 | $282 |
| AstraZeneca Pharmaceuticals LP | 9 | $213 |
| Merck Sharp & Dohme LLC | 8 | $187 |
| Exelixis Inc. | 14 | $155 |
| Daiichi Sankyo Inc. | 6 | $143 |
| Eisai Inc. | 9 | $140 |
| TerSera Therapeutics LLC | 6 | $135 |
| BeOne Medicines USA, Inc. | 8 | $127 |
| Celgene Corporation | 4 | $93 |
Products named: KEYTRUDA, CABOMETYX, Lenvima, IMFINZI, Fabhalta, KISQALI, TALVEY, BRUKINSA.
Industry payments across MS — which companies pay providers there.
